Novo Nordisk
June 23, 2026
Theater 2
Type: Company Presentation
Focus Area:
Metabolic Diseases
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our primary strategic focus is in obesity, diabetes and the related cardiometabolic diseases that impact these patients, including CVD, MASH and CKD, and rare blood disorders. In these areas, we are pioneering innovation, expanding access to our medicines, and working to prevent and ultimately cure disease.
Company HQ City:
Bagsvaerd
Company HQ State:
Bagsvaerd
Company HQ Country:
Denmark
Year Founded:
1923
Lead Product in Development:
Inventor of Semaglutide (Wegovy, Ozempic). Example of other lead program in development - CagriSema
CEO
Maziar Mike Doustdar
Development Phase of Lead Product
Multiple Products in Market
Exchange
NYSE
Ticker
NVO
When you expect your next catalyst update?
No comment
What is your next catalyst (value inflection) update?
Ziltivekimab readout in Q4 2026.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}